TCR2 Therapeutics Inc
NASDAQ:TCRR
Intrinsic Value
TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of TCRR.
TCR2 Therapeutics Inc's market capitalization is 58.1m USD.
TCRR stock price is 1.48 USD.
TCRR.
TCRR. Open DCF Valuation
TCRR. Open Relative Valuation
TCRR.
TCRR has negative Free Cash Flow for the last twelve months.
TCRR has negative Operating Income for the last twelve months.
TCRR has negative Net Income for the last twelve months.
TCRR's ROE (Return on Equity) has significantly decreased in the last 3 years from -29% to -91%, and is approaching profitability.
TCRR's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -179% to -217%, and is approaching profitability.
TCRR's ROE (Return on Equity) for the past 12 months is negative and is equal to -91%.
TCRR's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -217%.
TCRR's short-term assets (140m USD) exceed its short-term liabilties (47m USD).
TCRR's long-term assets (152m USD) exceed its long-term liabilties (50m USD).
TCRR has negative three-year average ROE (Return on Equity): -49%. The company is not efficient at transforming stockholders' equity into net income.
TCRR has negative three-year average ROIC (Return on Invested Capital): -504%. The company is not efficient at using invested capital to generate operating income.
TCRR's D/E (Debt to Equity) is very low and is equal to 0.
TCRR's Altman Z-Score is very low and is equal to -7.3.
Fundamental Analysis
TCR2 Therapeutics Inc
Balance Sheet Decomposition
TCR2 Therapeutics Inc
| Current Assets | 140.5m |
| Cash & Short-Term Investments | 110.3m |
| Other Current Assets | 30.2m |
| Non-Current Assets | 11m |
| PP&E | 9.2m |
| Other Non-Current Assets | 1.9m |
| Current Liabilities | 47.5m |
| Accounts Payable | 6.3m |
| Accrued Liabilities | 38.1m |
| Other Current Liabilities | 3m |
| Non-Current Liabilities | 2.7m |
| Other Non-Current Liabilities | 2.7m |
Earnings Waterfall
TCR2 Therapeutics Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-131.4m
USD
|
|
Operating Income
|
-131.4m
USD
|
|
Other Expenses
|
-31.7m
USD
|
|
Net Income
|
-163.1m
USD
|
Free Cash Flow Analysis
TCR2 Therapeutics Inc
TCRR Profitability Score
Profitability Due Diligence
TCR2 Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
TCR2 Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
TCRR Solvency Score
Solvency Due Diligence
TCR2 Therapeutics Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Score
TCR2 Therapeutics Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TCRR Price Targets Summary
TCR2 Therapeutics Inc
Ownership
TCRR Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
TCRR Price
TCR2 Therapeutics Inc
| Average Annual Return | 4.77% |
| Standard Deviation of Annual Returns | 107.83% |
| Max Drawdown | -98% |
| Market Capitalization | 58.1m USD |
| Shares Outstanding | 39 261 700 |
| Percentage of Shares Shorted | 1.16% |
Company Profile
TCR2 Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. The company is headquartered in Cambridge, Massachusetts and currently employs 137 full-time employees. The company went IPO on 2019-02-14. The firm's T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. Its lead TRuC-T cell, which targets solid tumors is gavocabtagene autoleucel (gavo-cel). The firm is conducting Phase I/II clinical trial for gavo-cel to treat patients with non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma and cholangiocarcinoma. Its other product candidates include TC-510, GPC3 and IL-15, which focuses on solid tumors, and CD70, which focuses on renal cell carcinoma. Its TC-510 is a TRuC-T cell targeting mesothelin-expressing solid tumors which incorporates a PD-1:CD28 chimeric switch receptor.
You don't have any saved screeners yet
